Chlorhexidine allergy in four specialist allergy centres in the United Kingdom, 2009–13: clinical features and diagnostic tests by Egner, W et al.
This is a repository copy of Chlorhexidine Allergy in 4 Specialist Allergy Centres in the UK, 
2009-2013: Clinical Features and Diagnostic Tests.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/112492/
Version: Accepted Version
Article:
Egner, W, Helbert, M, Sargur, R et al. (6 more authors) (2017) Chlorhexidine Allergy in 4 
Specialist Allergy Centres in the UK, 2009-2013: Clinical Features and Diagnostic Tests. 
Clinical and Experimental Immunology. ISSN 0009-9104 
https://doi.org/10.1111/cei.12944
© 2017 British Society for Immunology. This is the peer reviewed version of the following 
article: Egner, W, Helbert, M, Sargur, R et al. (2017) Chlorhexidine Allergy in 4 Specialist 
Allergy Centres in the UK, 2009-2013: Clinical Features and Diagnostic Tests. Clinical and 
Experimental Immunology. ISSN 0009-9104, which has been published in final form at 
https://doi.org/10.1111/cei.12944. This article may be used for non-commercial purposes in
accordance with Wiley Terms and Conditions for Self-Archiving. Uploaded in accordance 
with the publisher's self-archiving policy.
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
Chlorhexidine Allergy in 4 Specialist Allergy Centres in the UK, 
2009-2013: Clinical Features and Diagnostic Tests 
 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
Accepted Article, doi: 10.1111/cei.12944
This article is protected by copyright. All rights reserved.
Authors  
1. Dr.  William Egner           
Corresponding Author: william.egner@sth.nhs.uk 
Clinical Immunology and Allergy Unit 
Northern General Hospital 
Sheffield  
S5 7AU 
2. Dr.  Matthew Helbert 
Department of Allergy and Immunology  
Central Manchester University Hospitals NHS Foundation Trust 
Manchester, UK 
3. Dr.  Ravishankar Sargur  
Clinical Immunology and Allergy Unit 
Sheffield Teaching Hospitals NHS Trust 
Sheffield  
S5 7AU 
4. Mrs.  Kirsty Swallow 
Clinical Immunology and Allergy Unit 
Sheffield Teaching Hospitals NHS Trust 
Sheffield  
S5 7AU7AU 
5. Professor Nigel Harper 
Department of Anaesthesia  
Central Manchester University Hospitals NHS Foundation Trust 
Manchester, UK 
Page 2 of 29Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
6. Dr.  Tomaz Garcez  
Department of Immunology  
Central Manchester University Hospitals NHS Foundation Trust 
 Manchester, UK 
7. Dr. Sinisa Savic 
Department of Immunology,  
Leeds Teaching Hospitals 
Leeds, UK 
8. Dr. Louise Savic 
Department of Anaesthetics,  
Leeds Teaching Hospitals 
Leeds, UK 
  
9. Dr.  Eren Effren  
Department of Immunology 
Southampton General Hospital,  
Southampton, UK 
Abbreviations 
CI  Confidence Interval 
NMBA Neuromuscular Blocking Agent 
BAT  Basophil Activation Test 
SPT Skin Prick Test 
IDT  Intradermal Skin Test 
sIgE Specific IgE 
kUA/L   kilounits (arbitrary) of sIgE per litre 
Page 3 of 29 Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
SUMMARY 
 
We describe an observational survey of diagnostic pathways in 104 patients attending four 
specialist allergy clinics in the UK following perioperative hypersensitivity reactions to 
chlorhexidine reactions. The majority were life threatening.  Men undergoing urological or 
cardiothoracic surgery predominated.  Skin prick testing and sIgE testing were the most 
common tests used for diagnosis. Fifty-three % of diagnoses were made on the basis of a 
single positive test.  Where multiple tests were performed the sensitivity of intradermal, 
basophil activation and skin prick testing was 68% (50-86%), 50% (10-90%) and 35% (17-55%) 
respectively.  Seven percent were negative on screening tests initially, and 12 cases were only 
positive for a single test despite multiple testing.  Intradermal tests appeared most sensitive in 
this context. 
 
Additional sensitisation to other substances used perioperatively, particularly neuromuscular 
blocking agents (NMBA), was found in 28 patients, emphasising the need to test for possible 
allergy to all drugs to which the patient was exposed even where chlorhexidine is positive. 
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INTRODUCTION 
 
Chlorhexidine is increasingly recognised as a significant allergen in the perioperative setting 
[1].  We aimed to describe and compare a larger series of cases from multi-centre British 
specialist allergy clinics [1] [2].  This increase is thought to be driven by increased use of 
chlorhexidine and increased awareness of allergy, even though there remains some evidence 
of under-diagnosis [2] [3] [4].  Unlike most perioperative reactions [5], the majority of reported 
patients have been men, frequently undergoing urological or cardiothoracic surgery in non-UK 
and single centre studies.   
The performance of tests for chlorhexidine allergy has been estimated in single centres and 
there is published guidance on how to do tests for chlorhexidine allergy [6] [7], but it is not 
clear if these observations can be generalized to other clinic cohorts or countries [7].  We also 
set out to determine whether we could estimate sensitivity for the different tests available for 
diagnosing chlorhexidine allergy in a routine clinical setting and identify the most effective 
diagnostic strategy for determining sensitisation.  Finally, multiple reactivity has been reported 
in some individuals with well documented chlorhexidine allergy [3].  We evaluate how 
frequently potentially misleading multiple sensitisation is noted in our clinics.    
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MATERIALS AND METHODS 
Data collection   
Data on all patients diagnosed with chlorhexidine allergy was retrospectively collected from 
records of four regional UK Allergy Centres (Sheffield Teaching Hospitals, Central Manchester 
University Hospitals NHS Foundation Trust, Southampton University Hospitals, and Leeds 
Teaching Hospitals) between 2009 and 2015.  The patients were seen following routine 
referral into anaesthetic drug reaction clinics.  The investigations carried out were not 
harmonised across clinics.  Many of our series had only one test (most commonly SPT or sIgE) 
and the first positive test prevented further testing.  The sequence of further testing differed 
between centres (only one offered BAT), between patients and across time (increasing use of 
IDT in patient who were negative in screening tests in some centres).  As the data were 
collected as part of routine clinical audit, ethics committee approval was not required.  
Gender, chlorhexidine preparation used, the clinical setting, details of the reaction, 
investigations performed (skin prick and / or intradermal test, specific IgE and basophil 
activation test) and final clinical diagnosis were obtained.   
 
Skin prick testing (SPT) was carried out using undiluted clear or pink Hydrex
®
 (Chlorhexidine 
gluconate Solution 20% BP (Ph Eur) 2.5% v/v, denatured ethanol B 96%, purified water BP, 
Carmosine (E122)) with positive (histamine 10mg/ml) and negative (normal saline) controls:  
SPT was positive if a wheal ≥ 3mm than negative control was present at 15- 20 minutes, as 
reported previously and as per 2011 guidance [[7] [6].  All other drug skin prick tests were 
carried out in accordance with 2011 guidance.  Both pink & clear Hydrex was used to exclude 
any possible reactions due reactors to the colourant in some centres. 
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Intradermal testing (IDT) was performed using 20 microlitre injections of chlorhexidine 
gluconate (clear or pink or both, as appropriate to the clinic) 1:1000 dilution and normal saline, 
administered on the volar aspect of the forearm.  The results were interpreted as previously 
described [3] [7].  A positive IDT was defined as the mean of orthogonal weal diameters of at 
least 3mm greater than the negative control, in the presence of a flare [3] [7]. 
Chlorhexidine sIgE was measured by immunoassay (ImmunoCAP) on the Phadia ImmunoCap 
1000 Analyser (Thermo Scientific, Loughborough, UK).  A sIgE level >0.35 kUA/L was deemed 
positive in Sheffield, Leeds and Southampton and ≥ 0.4 kUA/L in Manchester (functionally 
equivalent to >0.35 as this laboratory reported measurement to a single decimal place only). 
All laboratories performed daily internal quality control and participated in the UK National 
External Quality Assurance Scheme for allergen specific IgE with satisfactory performance. 
 
At Sheffield and Southampton, Basophil Activation Tests (BAT, Buhlmann FlowCast, 
Switzerland) were analysed on a Beckman Coulter EPICS XL flow cytometer.  The chlorhexidine 
used to stimulate the basophils was from the same source as the skin prick tests.  
Chlorhexidine was used at concentrations of 0.05%, 0.005%, 0.0005% and 0.00005% for 
Hydrex
®
 “clear” and 0.02%, 0.002% and 0.0002% for Hydrex
®
 “pink”.   A wide range of 
concentrations were used to assess the strength of sensitisation and exclude potential irritant 
or toxic concentrations in patients and controls in view of the lack of experience, 
harmonisation and validation of this test. 
Positive controls (FcȜRI and fMLP), negative control (background) and a normal volunteer 
control were performed for each run.  Fluorescently labelled antibody to CCR3 was used to 
identify basophils.  Activated basophils were differentiated from resting basophils using a 
fluorescently labelled antibody to CD63, which only becomes expressed on the cell surface 
when basophils are activated [8].  A positive response was present if two or more 
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concentrations gave >5% basophil activation and a stimulation index >2.  The stimulation index 
was calculated by dividing the % of activated basophils at each concentration by the % of 
activated basophils in the background tube. 
 
Clinical reaction grading was in accordance with international guidance on reactions taking 
place in the perioperative setting (grade 1: Cutaneous signs, grade 2: Measurable but not life-
threatening physiological abnormalities, grade 3:  Life-threatening physiological abnormalities, 
grade 4: Cardiac and/or respiratory arrest) [6]. 
 
Patient inclusion criteria  
The clinical history of Type I hypersensitivity required involvement of two or more systems 
with defined symptoms [9].  This diagnosis was made by the submitting clinician.  The 
perioperative period was defined as admission for an invasive procedure, to their discharge or 
death.  In the absence of an agreed diagnostic gold standard for establishing chlorhexidine 
allergy, or a recognised and harmonised provocation test, we accepted a diagnosis of 
chlorhexidine allergy when there was a consistent clinical history for Type I hypersensitivity 
along with one or more positive tests demonstrating sensitization; i.e. the potential for an IgE 
mediated mechanism had been demonstrated)[7].  
Because each patient had different combinations of tests and test specificity was unknown we 
adopted a pragmatic strategy to assess test performance and compare with previous work.  In 
the absence of a gold standard test, such as provocation, assessment of individual tests to 
estimate the sensitivity is challenging.  Many of our series had only one test and the first 
positive test prevented further testing.  For patients with multiple tests we required a very 
rigorous demonstration of sensitisation for each test, with at least two additional positive 
allergy tests, as has previously been reported for chlorhexidine and rocuronium [7] [10].  For 
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the purposes of estimating individual test sensitivity, the result of the test being assessed for 
performance was omitted from diagnostic decision-making and results of the remaining tests 
were used to determine sensitisation status for chlorhexidine.  For example, when the 
sensitivity of SPT was being calculated, results of sIgE, IDT and BAT were used to determine 
allergy to chlorhexidine (where two confirmatory positive tests present).  We were unable to 
estimate specificity using these data because we did not analyse a series of patients without 
allergy, to whom the same tests were applied.   
  
RESULTS 
Clinical features 
134 patients were identified with a clinical diagnosis of chlorhexidine reaction; 18 patients had 
no positive tests (of whom, 11 had received only one test), one patient had not been tested 
and 12 patients had no evidence of perioperative reactions (referred because of occupational 
exposure or unexplained symptoms).  These 30 patients were excluded from the analysis.   
104 patients met our inclusion criteria having had a probable perioperative anaphylactic 
reaction to chlorhexidine.  66 patients were men.  Details of surgical interventions were 
available for 70 patients, of whom 16 had cardiac procedures and 13 urological procedures.  
Other specialties appear to be under-represented; for example, Obstetrics and Gynaecology 
procedures had only been carried out in 2 patients.   
The route of chlorhexidine exposure was reported in 53 patients, of whom 26 had only been 
exposed to chlorhexidine skin preparations.  Three patients had been exposed to chlorhexidine 
coated central venous catheters (CVC); 3 to sterile lubricating gel (Instillagel
TM
) and 3 to 
chlorhexidine mouth wash.  One patient had been exposed to chlorhexidine mouth spray only, 
and the rest to a combination of these products.   There were no clear relationships between 
the type of surgery and the chlorhexidine products used.  For example, cardiac patients were 
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exposed to combinations of chlorhexidine skin preparation, lubricating gel and coated CVCs 
(data not shown). 
 
The grade of reaction was available in 101 patients [6].  Most were severe grade 3 or 4; 
including grade 1 (9 patients), grade 2 (12 patients), grade 3 (72 patients) and grade 4 arrests 
(8 patients).   Grade 4 reactions were not associated with any particular type of surgery.  One 
of four patients in our analysis who was only exposed to chlorhexidine mouth wash/spray, 
experienced grade 4 anaphylaxis.   
Hypotension was the commonest individual symptoms and was described in 75 patients.  
Generalised urticaria was seen in 64, bronchospasm in 33 and angioedema in 21 patients.  
Localised urticaria was present in 3 and generalised flushing in 11.  There was no relationship 
between the presence of individual symptoms and different types of operation.  
Details of the timing of reactions were only available in 19 patients: 15 were described as 
“immediate perioperative” (i.e. within 15 minutes” ) and only 4 were delayed at 30 mins 
(grade 1 reaction),  30, 45 and 90 minutes (all grade 3 reactions).  Sequential mast cell tryptase 
results were available in 11 of these cases and showed a rise above baseline in 10 (not shown). 
 
Test results for entire series 
Because there was no harmonised testing pathway, different numbers and combinations of 
tests were used.  Skin prick test (SPT) were most common, performed in 93/104 patients and 
positive in 72 (77%). Specific IgE (sIgE) was assayed in 78/104 patients and positive in 62 (80%).  
Intradermal testing (IDT) was performed in 23/104 and positive in 21 (91%).  Basophil 
activation testing (BAT) was performed in 6 patients and positive in 3 (50%).  The distribution 
of positive tests is shown in Figure 1.  The mean sIgE levels and positive allergy tests for other 
substances for all 104 patients are shown in Table 1.   
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Results for patients who had three or more tests 
Figure 2 shows the distribution of positive tests amongst the 25 patients who had three tests.  
Table 2 shows the mean sIgE levels and positive allergy tests for other substances for these 
patients. 
For the analysis of the 25 patients who had three tests, we used 2 positive tests as a gold 
standard for making the diagnosis of chlorhexidine allergy in the presence of definitive 
sensitisation.  Using this approach, we were able to estimate the sensitivity and demonstrate 
that all three test modalities should be used when the screening test is negative, as shown in 
Table 3.   
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
   
 
 
  
 
Page 12 of 29Clinical Experimental Immunology
This article is protected by copyright. All rights reserved.
 Sensitisation to other potential triggers 
28/104 chlorhexidine allergic patients had evidence of reactivity to other potentially relevant 
allergens, including neuromuscular blocking agents (NMBA, 17 patients), morphine (4 patients) 
and a small number of other agents (see Table 1).   
 
Some patients had extreme multi-reactivity; for example, one patient who had two grade 
three anaphylactic reactions during orthopaedic procedures had positive SPT and sIgE to 
chlorhexidine (10.4 kUA/L) also had positive rocuronium IDT, and positive sIgE to 
suxamethonium, morphine and amoxicillin.   
 
NMBA positive patients appeared more likely to be chlorhexidine sIgE positive than NMBA 
negative patients (13/15 v 49/63).  This was not true for chlorhexidine IDT (6/7 v 15/16) or SPT 
(6/13 v 66/80); i.e.  NMBA positivity correlated better with sIgE than IDT or SPT testing.   
 
Multiple allergen reactivity was confirmed by the results of the patients who had 3 or more 
tests.  12 of the 25 patients who underwent three different chlorhexidine allergy tests, also 
showed evidence of allergy to other substances (Table 2), including seven patients with 
evidence of NMBA allergy.  Of these seven patients with evidence of NMBA allergy, 6 had 
positive chlorhexidine sIgE or IDT, whilst only one had positive chlorhexidine SPT.   
 
DISCUSSION 
Our report describes the largest single series of patients with perioperative chlorhexidine 
allergy so far published from routine clinical assessment.  It confirms and extends previous 
reports.  Our observations are based on data from routine clinical practice; therefore not all 
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patients underwent the same tests.  On the other hand, the data reflect existing clinical 
practice in the UK and should be less prone to bias than smaller reports of very specific types 
of reaction, for example those triggered by chlorhexidine coated CVCs.   
 
It is notable that our clinical data are consistent with previous descriptions of perioperative 
chlorhexidine allergy outside the UK.  For example, the majority of our patients were men and 
most reactions took place in Urology or Cardiothoracic surgery, as described previously [3] [4].  
Severe reactions are common, but may be subject to selection bias since these cases have 
been selected to be referred for specialist assessment, as is true for most previous series.  The 
explanation for the apparent underrepresentation of obstetric and gynaecological procedures 
is not clear. There is no clear reason why referral patterns for patients undergoing these 
procedures should differ from other surgical interventions as the majority of clinic referrals are 
made by anaesthetists. 
 
The majority of the reactions experienced by our patients were severe grade 3 reactions, most 
commonly including hypotension, with cardiac arrest occurring in a significant minority, as 
previously described  [1] [3] [4].  Hypotension is not a unique characteristic of reactions to 
chlorhexidine and has been shown to be a dominant feature of most perioperative allergic 
reactions [2] [11].   On the other hand, allergic reactions to penicillins or wasp venom appear 
to cause hypotensionless frequently  [1] [3] [4] [12][13] 
It is possible that perioperative allergic reactions, including those to chlorhexidine, tend to be 
more severe because the patient is unconscious and cannot respond to early symptoms.  In 
addition, many patients undergoing surgery have cardiorespiratory co-morbidity.  
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Diverse sources of chlorhexidine were triggers, and it is noteworthy that chlorhexidine 
mouthwash caused cardiac arrest in one patient.  Fatal reactions to topical chlorhexidine have 
been reported [14].   
Hidden chlorhexidine exposure is a known problem; in a recent systematic review of published 
cases of perioperative chlorhexidine allergy, coated CVCs accounted for a third of cases, but 
infrequently caused cardiac arrest [4].  In our group of patients, CVC exposure to chlorhexidine 
was not particularly common, but frequently caused hypotension and cardiac arrest.  It is not 
clear why our data on reactions triggered by chlorhexidine coated CVCs are different, but 
reporting bias may be relevant in small case series.  In addition, protocols for using 
chlorhexidine coated CVCs may differ between centres.   It is also possible that reactions to 
chlorhexidine coated CVCs are under-referred to our services.  Anaphylaxis to chlorhexidine 
coated CVCs may be difficult to diagnose, particularly if hypotension is the main feature and 
may be mistaken for anaesthesia-induced hypotension, haemorrhage from arterial puncture or 
pneumothorax.  Anaphylaxis induced by chlorhexidine has been confused with cardiogenic 
shock and sepsis [15][16].   Interestingly, the efficacy of chlorhexidine coated CVCs in 
preventing infection outside ICU has also been questioned by a Cochrane review [17].   
 
In an observational series such as this, and in the absence of a gold standard challenge 
procedure, only limited conclusions can be made about the performance of individual tests.   
Clearly the vast majority of diagnoses were supported utilising positivity in one of the two 
favoured tests (SPT or sIgE).   As a result, those patients who had multiple tests were either 
negative in the screening test or were selected in some other way for multiple testing.  True 
performance indices require unselected testing of all patients utilising all modalities.  Where 
multiple tests were used the majority of cases were positive in at least 2 tests.  However 9/104 
(8.7%) of the whole cohort were only positive in a single test representing 9/25 (36%) of the 
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cases where multiple tests were applied.  IDT appeared to be most sensitive as second line 
testing.  We cannot estimate specificity in routine practice, as we have not included individuals 
who definitely do not have chlorhexidine allergy[7] [10].  However, high sensitivity in testing 
for chlorhexidine allergy is arguably more important than specificity, as a false positive will 
only result in chlorhexidine being avoided, whilst a false negative could lead to repeat 
exposure and anaphylaxis.  
The basophil activation test was only ever positive in the presence of both sIgE and SPT, but is 
not available in most centres.    
One possible explanation for differences in test positivity favouring IDT when multiple tests are 
used is that chlorhexidine sIgE reactivity is lost over time and sIgE and the tests reported here 
may have been performed several months after the clinical reaction[3] [18].  However there 
were cases where sIgE and SPT were positive in the absence of IDT.  Table 3 clearly shows that 
IDT (and indeed SPT and sIgE) can be positive on its own and where screening tests are 
negative, thus further investigations should include IDT.  We cannot address the issue of 
whether the isolated positive IDT (or SPT, or sIgE) might be “false positive”, nor can any 
previous series, as we have no definitive challenge data.  UK clinics used 5mg/L chlorhexidine 
for IDT, whilst Opstrup used 2mg/L [7].  More prosaically, we will have excluded patients who 
had a positive SPT or sIgE and did not go on to have IDT in our sensitivity estimates in this 
subgroup analysis.  Thus Table 3 more closely estimates  the results of performing all test 
modalities where the screening test is negative, and shows that IDT clearly has a potential 
diagnostic advantage in this setting.   
 
 In addition, our IDT testing differed slightly from that previously used to validate IDT testing, 
in using the forearm rather than the back [7].  This variation is true of all skin tests in clinical 
practice, and argues strongly for adoption of harmonised approaches to skin testing. 
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 A combination of SPT and sIgE has been recommended as a high sensitivity strategy for testing 
for chlorhexidine allergy [7], based on data from a cohort of patients in whom testing ‘usually 
took place 2–4 months after the allergic reaction’.  Our data may support this observation 
since SPT and sIgE dominate the positive investigations in the whole cohort, but IDT dominates 
once these single test positives have been screened out.  It is noteworthy that 7 of our cohort 
of 104 patients, the only positive test was IDT.  Had IDT not been performed after finding 
negative SPT and sIgE, sensitization to chlorhexidine in these patients may not have been 
revealed. 
 
One logical approach would be to offer sIgE and SPT to all patients, but always to go on to do 
IDT if these tests are negative and there remains a high index of suspicion of chlorhexidine 
allergy.  
 
Positivity to other potential culprits in a third of our cases is important. Multiple sensitisations 
to drugs were common.  Twenty-eight of 104 patients had other positive allergy tests, 
confirming the finding of multiple reactivity in similar proportions to other cohorts of 
chlorhexidine allergic patients [3] [7].  However our patients mainly had reactivity to NMBAs, 
as opposed to the latex, opiates and beta lactams in the other reports.   
 
In our series, multiple reactivity occurred in patients with most combinations of chlorhexidine 
allergy tests, but was most closely associated with a positive chlorhexidine sIgE test.    
High total IgE (above 1500kUA/L) is a frequent cause of multiple reactivity in other settings.  
However, high total IgE is not thought to drive false positive chlorhexidine sIgE [18].  Until 
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neutralising and blocking experiments are reported, it remains unclear whether this multiple 
reactivity reflects cross reactivity, for example to quaternary amide groups.    
 
Twelve of the 25 patients who underwent three different chlorhexidine allergy tests, also 
showed evidence of allergy to other substances (Table 2), including seven patients with 
evidence of NMBA allergy.  Of these seven patients with evidence of NMBA allergy, 6 had 
positive chlorhexidine sIgE or IDT, whilst only one had positive chlorhexidine SPT.  This 
suggests that extended panels of allergen testing may be routinely required to ensure all 
potential triggers are assessed for clinical relevance.  It may also suggest that perioperative 
allergic reactions associate with multiple drug exposure or procedures. 
 
In summary, we report on the largest series yet described of patients diagnosed with 
chlorhexidine allergy.  We confirm that these reactions are frequently severe.  Specific IgE and 
SPT are reasonable first line tests for chlorhexidine allergy, but IDT should be added if these 
are negative, particularly if referral to the allergy clinic is delayed or if the index of suspicion is 
high.  False negativity in screening tests is not uncommon and may affect 7% of our series.  
Multiple sIgE reactivity is relatively common and, until further data are available on its cause 
and significance, should lead to specialist allergy assessment that looks for sensitization to all 
the potential drug triggers, and an imputibility assessment for each potential trigger, to avoid 
misdiagnosis.  Hidden exposure to chlorhexidine is common in healthcare environments and 
we suggest that awareness of the potential allergenicity of chlorhexidine should be part of the 
training of all healthcare professionals. Chlorhexidine coated CVCs were not a common trigger 
of anaphylaxis in UK cohorts, but did appear to be associated with severe reactions.   
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Table 1:  Combinations of test results in 104 Cases of Perioperative 
Chlorhexidine Allergy. 
Positive tests Number 
Patients 
(Pts) 
Mean  
Chlorhexidine  
sIgE  (kUA/L) 
(95% CI) 
Pts with other 
positive allergy 
tests* 
Pts with positive 
NMBA allergy tests 
Pts with other positive 
allergy tests 
Single pos IDT 7 0.34 (0-0.35) 3 1 x atracurium SPT 
1 x vecuronium & 
atracurium IDT 
1 x gelatine sIgE 
Single pos IgE 16 4.34 (0-16.52) 6 1 x rocuronium SPT 
1 x cisatracurium IDT 
2 x NMBA IDT & sIgE 
1 x QAM** sIgE 
1 x morphine sIgE 
1 x teicoplanin SPT 
Single pos SPT 32 0.34 (0-0.35) 4 1x atracurium SPT 1 x carmosine SPT  
1 x penicillin SPT 
1 x latex SPT 
Double pos  
IDT, sIgE 
9 8.50 (0-21.82) 7 1 x  vecuronium IDT & 
sIgE 
1 x all NMBAs IDT & 
sIgE   
1 x atracurium IDT 
1 x atracurium sIgE 
1 x teicoplanin IDT & SPT 
1 x amoxicillin sIgE 
1 x gentamycin IDT  
1 x  morphine IDT 
Double pos 
SPT, IDT 
3 0.34(0-0.34) 1 0 1 x gelatine IDT 
Double pos 
SPT, sIgE 
32 8.96 (0-27.92) 6 2 x all NMBA IDT 
1 x Rocuronium SPT & 
suxamethonium sIgE 
1x atracurium SPT 
1 x suxamethonium 
IDT & sIgE 
1 x QAM sIgE 
1 x morphine, 
amoxicillin sIgE 
Triple pos SPT,  
IDT, sIgE 
2 1.08 (0.17-1.99) 1 1 x suxamethonium 
sIgE 
1 x morphine SPT 
Triple pos SPT,  
sIgE, BAT 
3 6.18 (0-13.56) 0 0 0 
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Table 1 legend 
There was no correlation between the number and type of positive tests or sIgE level and 
reaction grade for the cohort of 104 cases (not shown).   
* Tests potentially relevant to the differential diagnosis of the reaction 
**QAM = Quaternary Ammonium Moiety (e.g. Thiocholine or Suxamethonium sIgE) 
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Table 2: The mean sIgE levels and distribution of positive allergy tests for 
other substances for 25 patients who tested positive for 2 or more 
chlorhexidine tests 
Patients who 
had three 
tests done  
Number 
of 
patients 
Mean 
Chlorhexidine SIgE  
(KUA/L) (95% CI) 
Patients with 
other positive 
allergy tests 
Patients with positive 
NMBA allergy tests 
Patients with other 
positive allergy 
tests 
Single pos IDT 5 0.34 (0-0.34) 2 1 x vecuronium & 
atracurium IDT 
1 x gelatine sIgE 
Single pos IgE 3 1.34 (0.59-2.09) 1 1 x NMBA IDT & sIgE1 0 
Single pos 
SPT 
1 0.34 1 0 1x carmosine SPT 
Double pos  
IDT, sIgE 
8 8.88 (0-23.07) 6 1x  vecuronium IDT & 
sIgE 
1 x all NMBAs IDT & 
sIgE   
1x atracurium IDT 
1 x atracurium sIgE 
1 x teicoplanin IDT 
& SPT 
1x amoxicillin sIgE 
 1 x gentamycin IDT  
1 x  morphine IDT 
Double pos 
SPT, IDT 
2 0.34 (0-0.35) 1 0 1 x gelatine IDT 
Double pos 
SPT, sIgE 
1 9.74 0 0 0 
Triple pos 
SPT, sIgE, BAT 
3 6.18 (0-20.88) 0 0 0 
Triple pos 
SPT, IDT, sIgE 
2 1.08 (0.17-1.99) 1 1 x suxamethonium 
sIgE 
1 x morphine SPT 
 
In the head to head comparison of SPT, sIgE and IDT, IDT was positive in 17/19 cases where 3 
tests were performed, more frequently than any other test.    
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Table 3: Sensitivity of each test modality in the 25 patients with at least 
2 positive chlorhexidine tests. 
 SPT sIgE IDT BAT 
True positives 9 17 17 3 
False negatives 16 8 2 3 
Sensitivity in cases with at 
least 3 tests 
(95% CI)  
36%* 
(17-55%) 
68% 
(50-86%) 
89% 
(75-100%) 
50% 
(10-90%) 
Published sensitivity  
[7]  
95% 100% 68% Not 
published 
 
* the majority of cases were diagnosed on basis of SPT or sIgE and this subgroup represents 
cases where multiple tests were used, predominantly because the initial screening test was 
negative. 
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 Figure 1 Legend 
The distribution of positive tests for all 104 patients.   
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Figure 2 legend 
25 patients had three tests.  All had SPT and sIgE.  6 patients also had BAT and 19 also had IDT. 
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